Skip to main content

Table 1 Sample characteristics

From: Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9

Sample group

Source

Sample type

Sample characteristic

Total number of samples

Number of females/males

Median (Mean) Age

Sample Set A

Plasma

Healthy

n/a b

92

47/45

60.0 (60.7)

PDAC a

Early Stage (I & II)c

20

6/14

68.5 (67.1)

   

Total

100

37/63

65.5 (63.7)

Sample Set B

Serum

Disease-free

n/a

47

34/11

51.0 (50.2)

PDAC

Early Stage (I & II)c

40

22/18

68.0 (66.1)d

Total

82

44/38

63.5 (63.8)

Benign

Neoplasm/adenomae

20

9/11

64.0 (60.0)

Pancreatitisf

21

10/11

59.0 (56.8)

Total

41

19/22

62.0 (58.3)

Other cancers

Colon

33

14/19

62.0 (63.0)

Liver

13

9/4

50.0 (56.2)

Stomach

5

2/3

75.0 (71.8)

Otherg

19

7/12

68.0 (62.6)

   

Total

70

32/38

62.5 (62.3)

  1. a PDAC, pancreatic ductal adenocarcinoma; b Not Applicable; c Stage was available for 47 PDAC samples from Sample Set A and 51 PDAC samples from Sample Set B; d One sample did not contain age information; e This group included intraductal papillary mucinous neoplasms (n = 10), serous/mucinous cystadenomas (n = 8), tubulovillous duodenal adenoma (n = 2); f Eighteen of 21 samples were listed as chronic pancreatitis; g Other includes ampullary cancer, Hodgkin’s lymphoma, renal cell carcinoma.